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Abstract: Although drug-eluting stents (DES) are successfully utilized for restenosis therapy, the development of local 
and systemic therapeutic means including nanoparticles (NP) continues. Lack of correlation between in vitro and in vivo 
studies is one of the major drawbacks in developing new drug delivery systems. The present study was designed to exam-
ine the applicability of the arterial explant outgrowth model, and of smooth muscle cells (SMC) cultures for prescreening 
of possible drugs. Elucidation of different species sensitivity (rat, rabbit, porcine and human) to diverse drugs (tyr-
phostins, heparin and bisphsophonates) and a delivery system (nanoparticles) could provide a valuable screening tool for 
further in vivo studies. The anticipated sensitivity ranking from the explant outgrowth model and SMC mitotic rates (por-
cine>rat>>rabbit>human) do not correlate with the observed relative sensitivity of those animals to antiproliferative ther-
apy in restenosis models (rat>rabbit>porcine>human). Similarly, the inhibitory profile of the various antirestenotic drugs 
in SMC cultures (rabbit>porcine>rat>>human) do not correlate with animal studies, the rabbit- and porcine-derived SMC 
being highly sensitive. The validity of in vitro culture studies for the screening of controlled release delivery systems such 
as nanoparticles is limited. It is suggested that prescreening studies of possible drug candidates for restenosis therapy 
should include both SMC cell cultures of rat and human, appropriately designed with a suitable serum. 
Key Words: Angioplasty/coronary intervention, cell culture / isolation, restenosis, smooth muscle cells.  
INTRODUCTION 
Percutaneous coronary interventions (PCI, balloon dila-
tion, endoluminal stenting, excisional atherectomy, intravas-
cular brachytherapy, and laser ablation) have revolutionized 
the treatment of coronary artery disease during the past two 
decades [1-3] A major recent advancement is the develop-
ment of local therapy by DES that dramatically reduce the 
incidence of in-stent restenosis up to <10% [4, 5]. The mode 
of action of the drugs released from DES, such as sirolimus 
(rapamycine) and paclitaxel (taxol), is the inhibition of SMC 
proliferation [6]. Nevertheless, the currently approved DES 
do not resolve all the problems arising from PCI. There are 
no DES that are applicable for challenging lesions such as 
lesions in small arteries, arterial intersection, and multiple 
injury sites [7]. In recent years, systemic therapies [8-11] and 
nanoparticles (NP) for systemic and local delivery are being 
developed [12-14]. The application of an apparently success-
ful drug and/or a delivery system in an animal model of 
restenosis (rat, rabbit, or porcine) to clinical trials has been 
frequently encountered with unexpected failures [1, 15-19]. 
The diverse effects between different experimental models 
including, tissue culture, animal models of restenosis, and 
clinical trials is no more evident than with heparin [18, 19].  
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Heparin has been found effective in various vascular SMC 
tissue cultures in vitro [20, 21], and in the rat and rabbit in-
jury models in vivo [18, 22]. Contradicting results were re-
ported in the porcine model [23, 24], it was found ineffective 
in a primate model [25], as well as in human clinical trials 
[18, 19]. 
For the facile development of the next generation of 
DES, and for the successful implementation of potential sys-
temic as well as local drug delivery treatments, there is a 
need for a reliable in vitro screening method of potential 
pharmacological agents. We hypothesized that appropriate 
cell or tissue culture studies can predict, to some extent, the 
outcome that will be obtained in vivo, and consequently in 
humans. 
This study was intended to address the specific questions 
of: Can cell culture studies of both free drug and drug em-
bedded in a polymer predict the results obtained in animal in 
vivo studies? And to this end, what is the preferred SMC 
culture species (rat, rabbit, porcine or human) and technique 
(cell or tissue cultures)? We evaluated the correlation be-
tween in vitro tissue culture results to that obtained in animal 
studies by examining several known anti-restenotic drugs of 
different categories; heparin, tyrphostins and bisphospho-
nates (BP). Heparin was examined in cell cultures of differ-
ent species in order to determine whether it's inactivity in the 
porcine model [24], and in humans [18, 19], following suc-
cessful in vitro [26] and in vivo studies [27-29] could have 
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taining an answer to the questions mentioned above, we have 
examined tyrphostins as a free drug or encapsulated in NP in 
cell cultures of various species [30, 31]. These low MW and 
hydrophobic protein tyrosine kinase (PTKs) inhibitors [32], 
have been shown to inhibit restenosis in various experimen-
tal models [12, 33, 34]. In addition, BP, bone-seeking agents, 
found to be effective in various animal models of restenosis 
following systemic administration in nanoparticles [35-37] 
were examined as a negative control. Unlike both heparin 
and tyrphostins which are effective SMC inhibitors, NP of 
BP exert their antirestenotic effect by a systemic immuno-
modulation, with no direct effect on SMC proliferation [35, 
36]. 
MATERIALS AND METHODS 
Outgrowth Rate of SMC from Arterial Explants 
Freshly dissected blood vessels from animals killed less 
than 5min prior to harvesting or from patients undergoing 
surgery, were placed in cold Ringer bicarbonate buffer. The 
arterial explants were used for the outgrowth model and 
SMC isolation. Animal arterial tissues used were, the ab-
dominal or carotid aorta of Sabra male rats (200-300g); ca-
rotid or abdominal arteries of juvenile porcine (15-20kg); 
and carotid arteries of New Zealand White rabbits (2.5 to 3.5 
kg), all of Harlan Laboratories, Jerusalem, Israel. The left 
internal mammary artery of patients undergoing bypass sur-
gery was utilized. The vessels were aseptically cleaned by 
removing the fat and connective tissue and were cut longitu-
dinally. The lumen side was gently scraped with a scalpel 
blade to dislodge endothelial cells, the vessel wall was cut 
with a scalpel blade into 2x2mm explants, and the luminal 
surface was gently pressed on fibronectin-coated surface (4 
explants/well). Explants were left to adhere undisturbed for 
1hr, 1ml of growth media was added and they were incu-
bated for 5 days. In rat explants, the medium contained, 10% 
fetal calf serum (FCS) high glucose (4500mg/l), penicillin 
(100U/ml), streptomycin (0.1mg/ml), nystatin (12.5U/ml), 
gentamycin (50g/ml) and glutamine (2mmol). Media con-
tained 15% inactivated porcine serum in porcine culture, 
15% inactivated rabbit serum in rabbit's culture, and 7.5% 
FCS and 7.5% human-pooled serum in human’s culture. The 
explants were placed in a humidifier incubator at 37°C and 
8% CO2 atmosphere, and the medium was changed every 2 
days. Each explant was scored every 2 days after the first 5 
days in order to determine the number of explants yielding a 
positive outgrowth of SMC. Positive outgrowth was defined 
as at least 2 cells emerging from the explant border. Scoring 
was continued until the percentage of explants yielding out-
growth was constant. Explants that had not adhered to the 
dish were not included in the analysis. 
Inhibition of SMC Outgrowth from Arterial Explants 
For studying the inhibition of SMC outgrowth, porcine 
explants were chosen since they exhibited the fastest growth 
rate. Medium with or without inhibitors (tyrphostin, AG-
1295 (6,7-dimethyl-2-phenylquinoxaline, Oz Chemicals, 
Jerusalem, Israel), heparin (Sigma-Aldrich, Israel), and 
bisphosphonates (alendronate (ALN), Unipharm, Tel-Aviv, 
Israel) was changed every 2 days thereafter. Each explant 
was scored every two days after the first 5 days as above. 
SMC Isolation and Culture 
Rat, porcine, rabbit and human SMC were isolated from 
explanted arteries and incubated as detailed above. Explants 
were aspired when the cells reached confluence, cells pas-
sages by trypsinization were placed in 5 or 10ml dishes, and 
the medium was changed every two days. Cells were used 
from the 1
st through the 4
th passage. Cells' identity was con-
firmed by means of microscopic observation and smooth 
muscle  -actin immunocytochemistry. Unless otherwise 
noted, all materials for cell cultures were purchased from 
Biologic Industries (Beit Haemek, Israel) and from Sigma, 
Israel. 
For growth assay, SMC were seeded (day 0) in fi-
bronectin coated 4-multiwell plates (10,000-15,000 cells/ 
well) in the respective growth media. On the following day 
(day 1), one plate was used to check the number of attached 
cells, and the medium was changed in the remaining plates 
with the same medium with or without growth factors and 
inhibitors. Medium was changed every 2 days, and the cells 
were counted by means of a Coulter Counter (Coulter Cor-
poration, Miami, FL, USA). For mitotic index determination, 
the cells’ replication rate was calculated as log2 (number of 
cells 6 days after plating divided by the number of cells 24hr 
after plating). For serum free medium (SFM) growth curves, 
cells were seeded in normal growth media at three different 
densities (low density (LD), 10,000 cells/well, medium den-
sity (MD), 30,000 cells/well and high density (HD), 50,000 
cells/well). In the following day, the medium was changed to 
SFM containing transferrin 25mg/ml, insulin 1mg/ml, sele-
nium 1.5*10-8M, cholesterol, vitamin E and taurine with or 
without serum. Medium was changed every 2 days, and cell 
number was determined. Proliferation was determined also 
by using the MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) assay. 
Inhibition of SMC Proliferation in Cell Culture 
Inhibition of cell proliferation was performed on SMC 
from passages 2 to 4. SMC were plated at 2x10
4 cells per 
well in 24-well plates and were allowed to grow overnight. 
Inhibitors studied were, tyrphostins (AG-1295, AG-1296, 
AG-1851, and AG-2033 [32]), heparin, and bisphosphonates 
(alendronate (ALN), risedronate, and clodronate (clod), 
Unipharm, Tel-Aviv, Israel, and ISA [2-(2-aminopyri- 
midino) ethyldiene-1,1-bisphosphonate acid betain], synthe-
sized in our group [38]. The drugs were utilized in their free 
form, in solution, or encapsulated in NP. Since tyrphostins 
were diluted in DMSO, the appropriate control used was the 
normal medium with the respective concentration of DMSO. 
The cells were then incubated at 37˚C for 48hr, and were 
counted. In addition, cell viability assay was performed [33, 
39].  
Nanoparticles Preparation 
Bisphosphonate NP 
A modified double emulsion-solvent evaporation tech-
nique was used to prepare NP of PLGA (poly(lactic-co-
glycolic acid)) containing alendronate [37]. Briefly, 0.5 ml 
of Polyvinyl alcohol, MW 30,000-70,000 (PVA, Sigma-
Aldrich, Israel) 2.8% solution in Tris buffer pH 7.4 contain-
ing 20 mg alendronate was emulsified in 3 ml of dichloro-62    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Epstein et al. 
 
methane (DCM, J.T. Baker) containing 3% PLGA (Sigma-
Aldrich, Israel) by sonication over an ice-bath using a probe 
sonicator (Microson XL, Misonix, Farmingdale, NY, USA), 
at 13 W output for 90 seconds. The resulting primary emul-
sion was added to a 2% PVA (20 ml) solution in Tris buffer 
pH 7.4 containing CaCl2 (Merck) at a 2:1 molar ratio of Ca 
to ALN, and sonicated for 90 seconds at 18 W output over 
an ice bath to form the double emulsion. DCM was elimi-
nated by 3 hr evaporation under magnetic stirring at 4°C. 
Tyrphostin NP  
NP containing the tyrphostin, AG-1295, were formulated 
using the modified nanoprecipitation method as previously 
described [33]. Briefly, 200 mg of d,l-PLA poly(d,l-lactide) 
MW 90,000–120,000 (Sigma, St. Louis, MO, USA) and 2mg 
of tyrphostin AGL-1295, (Oz Chemicals, Jerusalem, Israel) 
were dissolved in an organic phase of dichloromethane and 
acetone, 0.5 and 19.5ml, respectively. The aqueous phase 
was prepared by dissolving 50mg of the surfactant, pluronic 
F-68 (Sigma, St. Louis, MO, USA), in 40ml of distilled wa-
ter. The organic phase was rapidly poured into the aqueous 
solution under stirring on a magnetic plate leading to sponta-
neous formation of NP. The organic solvents were evapo-
rated, and formulation volume was adjusted to 10ml under 
vacuum that was gradually reduced from 180 to 12mmHg 
using Rotavapor (B. uchi, Switzerland) at 35ºC. Finally, the 
formulation was filtered through 0.45mm hydrophilic sy-
ringe filter (Sartorius, Germany).  
NP Characterization 
NP size, distribution and morphology were determined 
using photon correlation spectroscopy (ALV-GmBH, Lan-
gen Germany) and transmission electron microscope (TEM 
CM 12 Philips, Eindhoven, The Netherlands). The mean 
diameters obtained 223±64nm and 125±15nm, ALN and 
AG-1295 NP, respectively. The zeta potential was measured 
by means of a Zetamaster (ZEM, Malvern Instruments, Or-
say, France). The zeta potential obtained was, -4.4±0.9, and 
–0.3±0.1mV, ALN and AG-1295 NP, respectively. The fea-
tures of alendronate and AG-1295 loaded NP as well as 
blank NP are summarized in Table 1. 
Cell Internalization and Uptake of NP 
ALN-NP and AG-1295 NP cellular uptake was assessed 
by confocal microscopy (Zeiss LSM 410, Germany). Quanti-
tative uptake was determined by means of fluorescence acti-
vated cell sorting (FACS, Becton-Dickinson Immunocy-
tometry Systems, USA). Fluorescent NP were prepared us-
ing BODIPY (493/503) [12] or rhodamine (530/585). A 
PLA-BODIPY conjugate was synthesized in our lab from 8-
bromomethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-
diaza-s-indacene (Molecular Probes, Inc), and PLGA-NP 
labeled with rhodamine was synthesized in our lab PLGA 
rhodamin (1:10 ratio PLGA: PLGA Rhodamine, Molecular 
Probes, Inc). Fifty ml of the fluorescent NP suspension was 
mixed with the growth medium (0.5x10
6 cells/well), in a 
total concentration of 1mg/ml. Following 24hr of incubation, 
the cells were washed 3 times with PBS, fixed with formal-
dehyde (4%, 4min), and were washed another 3 times with 
PBS. The cells were observed using 543/570nm or 
493/503nm filters. For FACS analysis, following incubation 
the cells were washed 3 times with PBS containing 1% FCS 
and were analyzed according to their relative size, side scat-
tering and fluorescence intensity. NP with no fluorescent 
probe served as background for auto-fluorescence signals. 
Mean fluorescence intensity values were determined as lin-
ear values in the CellQuest software. 
Statistics 
All proliferation and inhibition experiments were per-
formed in triplicates, and the data is expressed as mean±SD. 
Results were analyzed by Kruskal-Wallis nonparametric 
ANOVA test, and Dunn’s multiple comparisons post-test 
was calculated when the p value was less than 0.05. p<0.05 
was considered significant, and p < 0.005 was considered 
very significant. 
RESULTS 
Cell and Tissue Culture Media 
Initially we examined the influence of serum type and 
concentration on the optimal conditions of SMC's outgrowth 
from arterial explants, and their growth in cell culture. Opti-
mal growth conditions of SMC were obtained only when 
serum was added (15% or 10% of medium), and when the 
serum used in the culture media was of the specific species. 
SMCs cultures of rat, rabbit and porcine species failed to 
replicate and to achieve a normal cell cycle in serum free 
medium (SFM) at all seeded densities (10,000, 30,000 and 
50,000 cells/well). The addition of 5% FCS to the medium 
improved the proliferation rate, from no replication to a low 
replication rate (the cells duplicated their number on day 5, 
but cell number was decreased afterwards; on day 12, cell 
number was as the initial seeding number). The addition of 
15% serum of the specific species in the rabbit, porcine, and 
human cultures yielded a linear growth curve, duplicating 
their number every 6 days. Similar growth was obtained for 
human cultures when the medium was supplemented with a 
Table 1.  The Physicochemical Properties of Nanoparticles Formulations Utilized in the Efficacy Studies 
Blank NP 
Formulation 
PLGA PLA 
ALN-NP Tyrphostin  NP 
Entrapment (%) (% of initial)      55.1±7.4  70.8±4.1 
Particle size (nm)  215±53  121±13  223±64  125±15 
Zeta potential (mV)  -2.5±0.7  -3.5±0.5  -4.4±0.9  -0.3±0.1 
 Predicting In Vivo Efficacy of Potential Restenosis Therapies by Cell  The Open Cardiovascular Medicine Journal, 2008, Volume 2    63 
 
mixture of human and FCS (7.5% each). Rat SMC were 
found to be the least sensitive and grew optimally in 10% 
FCS with no need of rat serum. All experiments were carried 
out afterwards with culture media supplemented with 15% 
serum of the specific species examined (rabbit and porcine), 
10% FCS in rat's cultures, and 15% serum (7.5% human se-
rum and 7.5% FCS) in human's cultures. 
Tissue Culture: SMC Outgrowth Rate from Arterial Ex-
plants 
The arterial explant model was developed in order to 
mimic SMC proliferation and migration from injured arteries 
in restenosis models [39, 40]. The cells migrating out from 
the explants of all species assumed the well-known hill-and-
valley shape [41, 42]. In initial experiments we wished to 
elucidate whether outgrowth rate is species-dependent. The 
rat and porcine explants exhibited outgrowth almost imme-
diately after plating, whereas human and rabbit explants ex-
hibited a delayed outgrowth (days 5 to 7; Fig. 1). Porcine 
cells were found to be the most proliferative among the spe-
cies examined ranking, porcine>rat>>rabbit>human (Fig. 1). 
Inhibition of SMC Outgrowth 
The effect of various drugs on SMC outgrowth rate was 
examined on porcine arterial-explants that exhibited the fast-
est outgrowth rate (Fig. 2). A marked prolongation of the 
time, from plating of the arterial tissue to the appearance of 
cells around the explants, was observed following treatment 
with heparin or AG-1295, but not after ALN or control 
treatment (Fig. 2). Heparin, and to some lower extent, AG-
1295 treatments resulted in ~50% inhibition of replication 
rate after 10 days. among the species examined. p<0.001 and 
p<0.05, porcine and human SMC vs. other species, respec-
tively. 
Cell Culture: SMC Proliferation and Viability 
The mitotic index of SMC proliferation was determined 
for all species, porcine derived cells exhibited the highest 
mitotic rate among the species examined ranking, por-
cine>rat>>rabbit>human (Fig. 3). 
Treatment of SMC of various species in cell culture with 
tyrphostins resulted in a marked reduction of SMC prolifera-
 
 
 
 
 
 
 
 
Fig. (1). Explants outgrowth curve from various species incubated in cell culture dishes. Medium was changed every 2 days after the first 
week. Note that rat and porcine explants outgrowth began almost immediately after plating, whereas human and rabbit explants displayed 
outgrowth only by day 5 to 7. 
 
 
 
 
 
 
 
 
Fig. (2). Inhibition effect of AG-1295, alendronate and heparin on SMC outgrowing from arterial porcine explants. Medium (with or without 
drug) was changed every 2 days after the first week. 64    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Epstein et al. 
 
tion. The response to the application of a representative tyr-
phostin, AG-1295, is depicted in Fig. (4) (similar results were 
obtained for the other tyrphostins, AG-1296, AG-1851 and 
AG-2033; data not presented). A similar dose-response rela-
tionship was found for all tested species, but with different 
grades of sensitivity. The ranking of sensitivity was found to 
be: rabbit>porcine>rat>>human (Fig. 4). As expected, hepa-
rin was found to be a potent antiproliferative drug of animal-
derived SMC, with sensitivity similar to that obtained with 
AG-1295 treatment (Fig. 5). No activity of heparin on hu-
man-derived SMC was observed, even at the highest concen-
tration of 1000g/ml (n=4); only 21% inhibition was achiev-
ed in comparison to more than 50% inhibition obtained in 
the rat, rabbit and porcine cultures at <400g/ml (Fig. 5). 
Drug Delivery Systems of NP and SMC Susceptibility 
Treatment of SMC by the tyrphostin, AG-1295, encapsu-
lated in NP resulted in a similar degree of inhibition as the 
free drug in solution (68%, Fig. 6). Empty NP spiked with 
the drug exhibited a similar inhibitory effect. Different sensi-
tivity was observed among the various species, rab-
bit>porcine>rat>human (Fig. 6). 
Alendronate loaded NP at 50M inhibited rat SMC pro-
liferation by 38±10%, and porcine, human, and rabbit SMC 
were inhibited by 45±16, 22±9 and 72%±21, respectively 
(Fig.  7). Species sensitivity was ranked, rabbit>porcine> 
rat>>human. Similar results were obtained with other BP; 
clodronate, risedronate and ISA encapsulated in NP (data not 
presented). As expected, treatment of SMC with free BP had 
no significant inhibitory effect on SMC proliferation and 
viability up to 100M regardless of the species utilized.  
In order to elucidate whether cell sensitivity is related to 
the different capability of the various species' SMC to inter-
nalize NP, fluorescent NP were utilized for assessing inter-
nalization. Non-labeled particles exhibited a very low fluo-
 
 
 
 
 
 
 
 
 
Fig. (3). Mitotic index of SMC proliferation of various species. Cells were plated at 1.5*10
4 cells per well in 24-well plates, and
 the rate of 
replication was compared 6 days following seeding. The cell replication rate was calculated as log2 (number of cells 6 days after plating / 
number of cells 24hr after plating). Porcine derived SMC were found as the most rapidly proliferating cells among the species examined. 
p<0.001 and p<0.05, porcine and human SMC vs. other species, respectively. 
 
 
 
 
 
 
 
 
Fig. (4). Dose response of inhibitory effect of AG-1295 on SMC from various species. For this experiment cells were plated at 2*10
4 cells 
per well in 24-well plates and allowed to grow overnight. Triplicate wells were then treated with rising concentrations of AG-1295 (5-
50M). The cells were then incubated at 37
0C for 48hrs and counted using a Coulter counter. AG-1295 caused a marked reduction of SMC 
proliferation in all species. Note that rabbit and human SMC exhibited the highest and lowest sensitivity. **P<0.001 human vs. other species. Predicting In Vivo Efficacy of Potential Restenosis Therapies by Cell  The Open Cardiovascular Medicine Journal, 2008, Volume 2    65 
 
rescent signal and were determined as background for further 
analyses. Confocal microscopy cross-sections verified cell 
internalization and the NP were localized in the cytoplasm 
24hr following incubation of fluorescent-labeled PLGA-NP 
(Fig. 8a). Similar experiments were carried out with PLA-
NP (encapsulating tyrphostins), and a lower extent of inter-
nalization was observed in comparison to PLGA-NP (encap-
sulating bisphosphonates). Quantification of the uptake was 
determined by FACS analysis. The highest uptake of parti-
cles was observed in human SMC up to a total of 60% of the 
cells, and to a lower extent in SMC of rat and rabbit, 30% 
and 10%, respectively (Fig. 8b). The higher internalization 
capacity of PLGA-NP in comparison to PLA-NP was ob-
served in all species. The ranking of uptake between the 
various cell species was determined as, human>rat>rabbit. 
DISCUSSION 
Typical development of new treatment modalities is cell 
culture studies of the chosen drug(s), animal studies in vari-
ous models of restenosis, and clinical studies. Apart from 
pharmacokinetics and pharmacodynamic considerations [34, 
43], it is expected that cell culture studies of potential 
antirestenotic drugs would confer the researcher with the 
drug of choice to be pursued in animal studies. 
 
 
 
 
 
 
 
 
Fig. (5). Dose response of heparin’s inhibitory effect on SMC proliferation of various species. For this experiment cells were plated at 2*104 
cells per well in 24-well plates and allowed to grow overnight. Triplicate wells were treated with rising concentrations of heparin (0.1- 
1mg/ml), the cells were incubated at 370C for 48hrs and counted using a Coulter counter. Heparin caused a marked reduction of SMC prolif-
eration of rat, porcine and rabbit (>60%, 0.4mg/ml). Note that human SMC were not affected at those concentrations. **p<0.001 human vs. 
other species.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Dose response and inhibitory effect on the proliferation of SMC from various species following treatment with AG-1295 in free 
form, encapsulated in PLA-NP or spiked formulation (blank NP with free drug). For this experiment cells were plated at 2*10
4 cells per well 
in 24-well plates and allowed to grow overnight. Triplicate wells were treated with rising concentrations of AG-1295 (5-50M). The cells 
were incubated at 37
0C for 48hrs and counted using a Coulter counter. AG-1295 caused a marked reduction of SMC proliferation in all spe-
cies. Note that no significant differences were observed between the various treatments (free drug, NP, or a spiked formulation), but species 
sensitivity was different. DMSO in the media served as control in AG-1295 experiments. 66    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Epstein et al. 
 
Initially, we established that serum of the specific species 
should be utilized in the culture media. Although rat SMC 
were found insensitive to the serum origin and could be suc-
cessfully cultured with FCS, all other species SMC were 
optimally grown only when the same species serum was 
used, partially (as in human-derived tissue and cell cultures, 
50% human serum with 50% FCS) or completely (as in rab-
bit and porcine-derived tissue and cell cultures). Moreover, 
when serum from different species is used misleading results 
could be obtained. Heparin treatment was apparently found 
as an effective inhibitor of SMC proliferation in human-
derived SMC culture containing only FCS [20, 44], but inef-
fective when human serum was included in the cell culture 
media (Fig. 5). This is probably because growth factors and 
cytokines of each species have a limited cross-reactivity. 
The arterial-explant culture model is an attractive model 
for screening of potential antirestenotic drugs since it is ap-
parently mimicking the tissue response to injury. Outgrowth 
initiation was considered as the immediate response to injury 
manifested by a transformed population of cells able to mi-
grate out of the tissue and proliferate. In this model, human 
explants exhibited a longer time of outgrowth initiation than 
animal-derived explants (Fig. 1), and the outgrowth rate was 
ranked as: porcine>rat>>rabbit>human. Similarly, the mi-
totic index obtained in SMC cultures followed the same 
ranking (Fig. 3). This ranking indicates that animals' sensi-
tivity to an antiproliferative treatment would be expected to 
be: porcine>rat>rabbit. This prospect is not in complete ac-
cord with the results obtained in animal studies of restenosis. 
The sensitivity of various animals to heparin treatment is, 
rat>rabbit>>porcine [15, 23, 24, 29, 45, 46]. In addition, the 
same ranking of animals’ sensitivity for tyrphostins treat-
ments in restenosis models is observed [12, 33, 34, 39, 47]. 
Moreover, heparin was found somewhat more potent than 
AG-1295 in the porcine arterial explant model (Fig. 3). Nev-
ertheless, when those antiproliferative drugs were tested in 
the porcine model of restenosis, AG-1295 [39] and other 
tyrphostins [12, 33] exhibited significant efficacy, whereas 
mixed results were reported for heparin's efficacy [23, 24, 29].  
The anticipated sensitivity ranking from the explant out-
growth model and SMC mitotic rates are not in accordance 
with the observed relative sensitivity of various animal spe-
cies to antiproliferative therapy in restenosis models. On the 
other hand, it is expected from the arterial explant outgrowth 
model that the human (Fig. 1) would be the least sensitive to 
an antiproliferative treatment. Indeed, heparin was found 
ineffective in clinical trials [16, 18, 19]. 
As can be evidenced, heparin, even at a high concentra-
tion of 1mg/ml, exhibited no antiproliferation effect on hu-
man SMC (Fig. 5), in accord with heparin's inactivity in hu-
man trials [16, 18, 19]. In addition, the profound antiprolif-
erative activity exhibited by AG-1295 on SMC of various 
animal species has been reported to be successfully repro-
duced in vivo [34, 39]. The ranking of species sensitivity in 
SMC culture to AG-1295 and heparin was rabbit>porcine> 
rat>>human (Figs. 4-5). The rabbit and porcine SMC were 
the most sensitive. The reason(s) underlying this ranking of 
activity is unknown and beyond the scope of this work. Ge-
netic variability could explain the variability in response to 
different drugs among species as was suggested for SMC 
cell types of different responsiveness [48]. It should be noted 
that the above ranking of sensitivity is not inversely corre-
lated to the mitotic index (porcine>rat>rabbit>human, Fig. 
3). The mitotic index could represent the relative age of the 
species (juvenile pigs on one hand and old humans on the 
other, rats and rabbits in-between). It is suggested that pre-
screening studies of possible drug candidates for restenosis 
therapy should include both SMC cell cultures of rat and 
human, appropriately designed with a suitable serum. 
Moreover, examination of possible candidates for restenosis 
inhibition in cell culture models could be performed in rat 
and human SMC cultures, and not necessarily in the same 
species intended to be examined in vivo. It should be recalled 
that both taxol and sirolimus, utilized clinically in DES, ex-
hibited profound inhibition of porcine as well as human-
derived SMC in culture [49].  
It remains unclear whether any single restenotic animal 
model is of a more predictive value than others to the human 
response, and what species is a better predictor for a specific 
antirestenotic treatment [1, 46, 50]. Stenting of porcine coro-
nary artery or the rabbit iliac artery are the most frequently 
used animal models for in-stent restenosis [45, 51]. 
 
 
 
 
 
 
 
Fig. (7). In vitro inhibition of SMC proliferation of various species; rat, rabbit, porcine and human, by alendronate encapsulated in NP 
(50M) in comparison to blank NP. Cells were plated, allowed to grow overnight, treated with 50M alendronate or equal amount of blank 
NP, incubated for 48hr, and counted using a Coulter counter and MTT assay. The grade of sensitivity obtained was identical for both treat-
ments, rabbit>porcine>rat>>human. Predicting In Vivo Efficacy of Potential Restenosis Therapies by Cell  The Open Cardiovascular Medicine Journal, 2008, Volume 2    67 
 
In vivo studies in the rat and porcine models revealed a 
rapid biodegradation of AG-1295 when administered in solu-
tion [30, 39]. Encapsulation of tyrphostins in NP and polym-
eric matrices was shown to maintain drug stability, with a 
sustained release profile that matches the time course of the 
pathologic processes [31]. However, the significant advan-
tage of NP over free drug could not be detected in vitro (Fig. 
6). This is probably because there is neither drug wash out 
nor biodegradation as occurs in vivo, and internalization of 
the NP parallels the efficient transport of the hydrophobic 
tyrphostin into the cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Uptake of SMC from various species (rat, rabbit, and human) incubated with fluorescently labeled PLGA-NP (Rhodamine) 24hr 
following treatment. a) Confocal cross-section images of SMC incubated with fluorescent NP. Note the uptake of NP, and the extensive in-
ternalization by human SMC. The NP were localized in the cytoplasm. b) Fluorescence intensity histogram of SMC detemined by FACS 
following application of fluorescent-labeled PLGA-NP with Rhodamin, and PLA-NP with BODIPY, 24hr after incubation. Note that inten-
sity was higher in all species for PLGA-NP (pink) than PLA-NP (green), with extensive uptake of PLGA-NP in human SMC (60%) in com-
parison to 20% and 10%, rat and rabbit SMC, respectively. 68    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Epstein et al. 
 
Although SMCs aren’t phagocytic, they posses the capa-
bility to uptake and internalize polymeric nanoparticles [12]. 
The preferential uptake of PLGA-NP in comparison to PLA-
NP by SMC by all species (rat, rabbit and human, Fig. 8b) 
could be explained by the negatively charged surface of 
PLGA vs. the neutral charge of PLA NP [52, 53]. It is well 
known that charged particles are avidly internalized by 
phagocytic cells [54, 55]. It is plausible to assume that the 
adsorbed proteins on the negatively charged NP contributed 
to internalization. 
In vivo results obtained in our group have shown that 
treatment with BP in free form or encapsulated in NP, in the 
rat and rabbit models of restenosis, do not influence SMC 
directly [35-37, 56]. The reduction of cell proliferation is 
attributed to decreased inflammation response in the artery, 
following inhibition of circulating monocytes and depletion 
of arterial macrophages [35-37, 56]. It is interesting to note 
that NP internalization followed the ranking of: hu-
man>rat>rabbit (Fig. 8), but rabbit-derived SMC were found 
as the most sensitive to ALN-NP treatment (Fig. 7). It is 
suggested that the unique sensitivity of rabbit SMC detected 
in the SMC culture studies (Fig. 7) contributed to the pro-
found effect of ALN-NP rather than their internalization ca-
pability. Taken together, the similar effects exerted by AG-
1295 NP, free drug and spiked NP (Fig. 6) and the effects of 
ALN NP (Fig. 7), it can be concluded that the validity of in 
vitro culture studies for screening controlled release delivery 
systems such as NP is limited. 
CONCLUSIONS  
Reliable SMC culture studies can be obtained if the se-
rum of the specific species is utilized in the culture media. It 
is advisable to examine a new drug candidate in the rat and 
human SMC cultures. Prescreening of possible drug candi-
dates for restenosis therapy should always include studies in 
human-derived SMC culture, which included human serum.  
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